Portal de investigação
Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Klimek, L
- Czarlewski, W
- Anto, JM
- Bedbrook, A
- Kvedariene, V
- Ventura, MT
- Ansotegui, IJ
- Bergmann, KC
- Brussino, L
- Canonica, GW
- Cardona, V
- Carreiro-Martins, P
- Casale, T
- Cecchi, L
- Chivato, T
- Chu, DK
- Cingi, C
- Costa, E.
- Cruz, AA
- De Feo, G
- Devillier, P
- Fokkens, WJ
- Gaga, M
- Gemicioglu, B
- Haahtela, T
- Ivancevich, JC
- Ispayeva, Z
- Jutel, M
- Kuna, P
- Kaidashev, I
- Kraxner, H
- Larenas-Linnemann, DE
- Laune, D
- Lipworth, B
- Louis, R
- Makris, M
- Monti, R
- Morais-Almeida, M
- Mösges, R
- Mullol, J
- Odemyr, M
- Okamoto, Y
- Papadopoulos, NG
- Patella, V
- Nhân, PT
- Regateiro, FS
- Reitsma, S
- Rouadi, PW
- Samolinski, B
- Sova, M
- Todo-Bom, A
- Taborda-Barata, L
- Tomazic, PV
- Toppila-Salmi, S
- Sastre, J
- Tsiligianni, I
- Valiulis, A
- Wallace, D
- Waserman, S
- Yorgancioglu, A
- Zidarn, M
- Zuberbier, T
- Bousquet, J
- Pfaar, O
Unidades de investigação
Abstract
Background Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air(R) app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods We assessed the MASK-air(R) data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales-VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = -12.1;-2.8), lower VAS Work (average difference = 5.0; 95%CrI = -8.5;-1.5), and a lower CSMS (average difference = 3.7; 95%CrI = -9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = -17.2;-2.8), lower VAS Work (average difference = 7.8; 95%CrI = -15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = -18.5;0.2). Conclusion In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its 'real-world' effectiveness.
© 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Dados da publicação
- ISSN/ISSNe:
- 2045-7022, 2045-7022
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.1002/clt2.12128
- Link para outro recurso:
- www.scopus.com
Clinical and Translational Allergy John Wiley & Sons Inc.
Citações Recebidas na Web of Science: 8
Citações Recebidas na Scopus: 13
Documentos
- Não há documentos
Filiações
Keywords
- allergic rhinitis; immunotherapy; mobile health; patient-reported outcomes; real-life data analysis
Campos de estudo
Financiamento
Proyectos asociados
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (EPI-ASTHMA) - NCT05169619
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (EPI-ASTHMA) . AstraZeneca . 2021
Effect of a Mobile App on Improving Asthma Control in Adolescents and Adults With Persistent Asthma: A Pilot Randomized Multicentre, Superiority Clinical Trial (mINSPIRERS) - NCT05129527
Investigador Principal: João de Almeida Lopes da Fonseca
Ensaio Clínico Académico (mINSPIRERS) . 2021
Bioavailability of EPA + DHA Enriched Canned Tuna and Its Acute Effects on Cardiovascular Risk Markers, in Healthy Human Volunteers (FUNCTIONALTUNA) - NCT03742492
Investigador Principal: Luís Filipe Ribeiro de Azevedo
Ensaio Clínico Académico (FUNCTIONALTUNA) . CINTESIS . 2019
Utilização em estudos observacionais do Registo de Asma Grave Portugal.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Observacional Académico (RAG) . 2020
Clinical Research Collaboration Severe Heterogenous Asthma Research collaboration, Patient-centered (CRC SHARP).
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (SHARP) . European Respiratory Society . 2021
Seroprevalence of SARS-CoV-2 and assessment of epidemiologic determinants in Portuguese municipal workers
Investigador Principal: Bernardo Manuel De Sousa Pinto
Estudo Clínico Académico (SARS-CoV-2) . 2021
Use of secondary data, health technology assessment methods and economic modelling applied to penicillin allergy
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Using different data sources for the identification of asthma patients and those at high risk of adverse outcomes
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Phenotypes of Chronic Diseases of the Airways: Towards Multidimensional Data -Driven Profiling
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Health Tecnology Assessment of Nutrition an Food Productd - The Scientific Evidence Behind Health Claims
Investigador Principal: Luís Filipe Ribeiro de Azevedo
Estudo Clínico Académico . 2020
Comparative effectiveness of opioid therapy for the long term management of chronic non cancer pain
Investigador Principal: Luís Filipe Ribeiro de Azevedo
Estudo Clínico Académico . 2020
Citar a publicação
Sousa B,Azevedo L,Sa A,Vieira R,Amaral R,Klimek L,Czarlewski W,Anto JM,Bedbrook A,Kvedariene V,Ventura MT,Ansotegui IJ,Bergmann KC,Brussino L,Canonica GW,Cardona V,Carreiro P,Casale T,Cecchi L,Chivato T,Chu DK,Cingi C,Costa E,Cruz AA,De Feo G,Devillier P,Fokkens WJ,Gaga M,Gemicioglu B,Haahtela T,Ivancevich JC,Ispayeva Z,Jutel M,Kuna P,Kaidashev I,Kraxner H,Larenas DE,Laune D,Lipworth B,Louis R,Makris M,Monti R,Morais M,Mösges R,Mullol J,Odemyr M,Okamoto Y,Papadopoulos NG,Patella V,Nhân PT,Regateiro FS,Reitsma S,Rouadi PW,Samolinski B,Sova M,Todo A,Taborda L,Tomazic PV,Toppila S,Sastre J,Tsiligianni I,Valiulis A,Wallace D,Waserman S,Yorgancioglu A,Zidarn M,Zuberbier T,Fonseca J,Bousquet J,Pfaar O. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model. Clin. Transl. Allergy. 2022. 12. (3):e12128. IF:4,400. (2).
